Abivax, an advanced clinical stage biotechnology company, is developing novel therapies that modulate the body’s natural immune system to treat patients with chronic inflammatory diseases, viral infections, and cancer. Abivax leverages its immune enhancing and antiviral platforms to provide innovative and effective solutions in these therapeutic areas with significant unmet medical needs.
Based in Paris and Montpellier, Abivax has two promising drug candidates in clinical development: ABX464 to treat ulcerative colitis, Crohn’s disease and rheumatoid arthritis as well as ABX196 for the treatment of hepatocellular carcinoma.
Lead molecule ABX464 is a highly differentiated oral drug candidate, with a novel mechanism of action based on the upregulation of a single microRNA (miR-124). In preclinical and clinical studies, the molecule has demonstrated safety and profound and maintained anti-inflammatory activities.
Abivax at a glance:
|Field of Activity||Abivax focuses on the clinical development of ABX464 in chronic inflammatory diseases, notably in inflammatory bowel diseases (IBD) such as ulcerative colitis and Crohn’s disease as well as in rheumatoid arthritis. All three diseases are very debilitating for the patients and present with high medical needs, as too many patients do not respond or loose responsiveness to current therapies. In addition, the safety profile of many of these treatments is often suboptimal. The commercial opportunity for ABX464 in these first chronic inflammatory indications is above USD 40B.|
|Ownership Structure and Financing||Publicly listed on the Paris Stock Exchange since 2015, with Truffle Capital and Sofinnova Partners as major shareholders.|
|Selected Abivax Programs||Three clinical studies ongoing or planned with ABX464:
• Global phase 3 clinical program in ulcerative colitis to start end of 2021
Further, a phase 1/2 clinical trial with ABX196 is ongoing for the treatment of hepatocellular carcinoma.
|Unique Selling Point||ABX464 is a first-in-class small molecule with the ability to selectively upregulate miR-124, a potent anti-inflammatory micro-RNA. ABX464 has shown a good safety profile in over 850 patients and volunteers and impressive short-term and long-term efficacy in phase 2a and 2b studies (covering induction and maintenance protocols) in patients with moderate-to-severe ulcerative colitis and in a phase 2a induction study in RA.
Along with the convenient once-daily oral dosing of ABX464, the unique mechanism of action might render this drug candidate attractive for combination therapies.
|Date of Incorporation/
Number of Employees
|Address||5, rue de la Baume
|Telephone/-fax||+33 1 53 83 08 41|
|Social Media||LinkedIn Twitter|